BDTX - Black Diamond Therapeutics, Inc.
IEX Last Trade
2.295
0.015 0.654%
Share volume: 3,512
Last Updated: Thu 26 Dec 2024 08:30:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.28
0.02
0.66%
Fundamental analysis
27%
Profitability
41%
Dept financing
18%
Liquidity
50%
Performance
8%
Performance
5 Days
0 0%
1 Month
-11.34%
3 Months
-50.34%
6 Months
-53.30%
1 Year
-26.76%
2 Year
69.77%
Key data
Stock price
$2.30
DAY RANGE
$2.20 - $2.28
52 WEEK RANGE
$2.20 - $7.66
52 WEEK CHANGE
-$27.72
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: David M. Epstein
Region: US
Website: blackdiamondtherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: blackdiamondtherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Black Diamond Therapeutics, Inc. discovers, develops, and commercializes medicines for patients with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by non-canonical epidermal growth factor receptor (EGFR) mutations. The company is also developing a brain-penetrant inhibitor of EGFR mutations.
Recent news